TIE Video Library Page


		Is HIV Treatment HIV Prevention? Part One Mark Cloutier, CEO, San Francisco AIDS Foundation, San Francisco, California, USA. Judith Auerbach, PhD, VP, San Francisco AIDS Foundation, San Francisco, California, USA. Robert M Grant, MD, MPH, Associate Professor, Investigator, Gladstone Institute of Virology, UCSF, San Francisco, California, USA. Lisa C Capaldini, MD, Clinical Director, Castro Medical Group, Assistant Clinical Professor of Medicine, UCSF, San Francisco, California, USA. Maupali Das-Douglas, MD, Director of Research, HIV Prevention Section, SFDPH, Assistant Clinical Professor, AIDS/Infectious Diseases, UCSF, San Francisco, California, USA. Dana Van Gorder, Executive Director, Project Inform, San Francisco, California, USA.	Part one of a two part program produced and distributed through a collaborative community effort. Thank You All! We apologize for the sound quality.
		Is HIV Treatment HIV Prevention? Part Two Mark Cloutier, CEO, San Francisco AIDS Foundation, San Francisco, California, USA. Judith Auerbach, PhD, VP, San Francisco AIDS Foundation, San Francisco, California, USA. Robert M Grant, MD, MPH, Associate Professor, Investigator, Gladstone Institute of Virology, UCSF, San Francisco, California, USA. Lisa C Capaldini, MD, Clinical Director, Castro Medical Group, Assistant Clinical Professor of Medicine, UCSF, San Francisco, California, USA. Maupali Das-Douglas, MD, Director of Research, HIV Prevention Section, SFDPH, Assistant Clinical Professor, AIDS/Infectious Diseases, UCSF, San Francisco, California, USA. Dana Van Gorder, Executive Director, Project Inform, San Francisco, California, USA.	Part two of a two part program produced and distributed through a collaborative community effort. Thank You All! We apologize for the sound quality.
		Everything You Wanted to Know About Influenza Carol Opheikens, RN BSN PHN, Adult Immunization Coordinator, Oregon Immunization Program, Portland, Oregon, USA. Joyce Caramella, RN, Chair OAIC Quality Improvement Coordinator, CareOregon, Portland, Oregon, USA. Stephen Allred, Nurse Practitioner, Clinical Director, GetAFluShot.com, Portland, Oregon, USA.	This program was produced through collaboration with the State of Oregon and health advocacy organizations to improve the prospect of at-risk populations surviving the cold and influenza season through immunization and lifestyle changes. This is one of the most important programs IFARA produces annually as recommendations presented by the presenters and headed by the viewing audience can lead to a substantial reduction in acquisition of influenza virus.
		America's Dirty Little Secret: Are We Getting Worse? Judy Daly, Primary Children's Medical Center, Salt Lake City, Utah, USA. Brian Sansoni, Soap & Detergent Association, Washington, District of Columbia, USA.	Survey Finds Decline in Handwashing Behavior in Public Restrooms...When it comes to washing their hands, Americans say they are getting the message, but their actions speak otherwise. While nine out of ten (92%) Americans, in a recent telephone survey, said they always wash their hands after using a public restroom, an observational survey in 5 cities found the actual number to be more like 3 out of 4 (77%). That's down nearly 10 percent from a similar study done in 2005, and it's all men's fault. The percentages of males observed washing their hands fell from 75% in 2005 to 66% in 2007. Overall, percentage of females observed washing their hands is only down slightly from 90% in 2005 to 88% in 2007. Representatives of the American Society for Microbiology and the Soap & Detergent Association will present the findings of this survey and discuss the implications.
		Opening Press Briefing 47th I.C.A.A.C. Meeting Scott Hammer, Columbia University, New York, New York, USA. M. Lindsay Grayson, Austin Hospital/Austin Health, Melbourne, Australia. Karen Bush, Johnson & Johnson Pharmaceutical R & D, Raritan, New Jersey, USA.	Members of the ICAAC Program Committe will give an overview of the ICAAC meeting and discuss sessions of particular interest.
		New Viruses: Old Diseases? David Wang, Washington University School of Medicine, St Louis, Missouri, USA. Kenneth McIntosh, Harvard Medical School, Boston, Massachusetts, USA. Malik Peiris, Queen Mary Hospital, Pokfulcam, Hong Kong, SAR, PRC. Kate Ward, University College, London, United Kingdom	Until recently, our understanding of viruses and what diseases they cause has been heavily biased towards those viruses that scientists were able to grow in culture. New DNA-based detection methods have allowed scientists to better identify and characterize viruses associated with disease. Over the past five to seven years, through molecular discovery techniques several new respiratory viruses have been found in infants and children with respiratory disease, and, because of improved diagnostics, several old viruses have been found much more commonly than they were before. Researchers will present epidemiological data on these new viruses as well as the symptoms and disease they are believed to cause.
		The Future of Tuberculosis Treatment Ken Duncan, Bill & Melinda Gates Foundation, Seattle, Washington, USA. Jacques Grosset, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Melvin Spigelman, Global Alliance for TB Drug Development, New York, New York, USA.	Tuberculosis continues to be one of the world's deadliest infectios diseases. Each year it is responsible for approximately 1.6 million deaths globally. It is a tough disease to fight, requiring months of antibiotic therapy to cure, and it keeps getting stronger. No longer are there just multi-drug resistant strains, but now there are extensively drug-resistant strains, immune to almost all antibiotics, appearing around the world. What is being done to fight it? What new treatments for tuberculosis can we see on the horizon? Participants will discuss what's being done to accelerate drug discovery, outline new tuberculosis treatments currently in Pase I, II, and III clinical trials and present new data from animal models that suggest a reformulation of existing antibiotics might shorten tuberculosis treatment from months to weeks.
		Where Will Future Antibiotics Come From? Richard Baltz, Cubist Pharmaceuticals Inc., Lexington, Massachusetts, USA. Karen Bush, Johnson & Johnson Pharmaceutical R & D, Raritan, New Jersey, USA. Robert Hancock, University of British Columbia, Vancouver, British Columbia, Canada. Steven Projan, Wyeth Research, Cambridge, Massachusetts, USA. Lynn Silver, LL Silver Consulting, LLC, Springfield, New Jersey, USA.	It's a vicious cycle that has been going on since the discovery of penicillin. As bacteria are exposed to antibiotics, they eventually develop resistance, forcing scientists to search for more new antibiotics, to which the bacteria will eventually develop resistance. But from where will these new antibiotics come? Representatives of the pharmaceutical industry as well as academics will give an overview of the current areas of research into antibacterials and discuss their potential as sources of new antibiotics.
		The Unexpected Antimicrobial Effects of Cholesterol Reducings Drugs Jon Cohen, Brighton and Suxxex Medical School, Brighton, United Kingdom.	There has been anecdotal evidence that people taking the family of cholesterol lowering drugs known as statins rarely develop severe sepsis, a leading cause of death in intensive care units. Now, researchers present data that suggesting that statins may help prevent the development of severe sepsis by exerting an antibiotic effect in the bloodstream.
		The Benefits of Pertussis Vaccine at Birth Nicholas Wood, National Center for Immunisation Research & Surveillance of Vaccine Preventable Diseases, Westmead, New South Wales, Australia.	Late-breaking data from Australia suggest that adding a pertussis vaccination at birth mey greatly enhance immunity to the disease later in life.
		Novel Treatments for C. difficile Nebojsa Janjic, Replidyne Inc., Louisville, Colorado, USA. Usha Stiefel, Case Western Reserve University, Cleveland, Ohio, USA.	Clostridium difficile bacteria are a common cause of antibiotic associated diarrhea, especially in hospital settings. According to the Centers for Disease Control and Prevention, each year in the United States C. difficile is responsible for tens of thousands of cases of diarrhea and at least 5,000 deaths. It's also a growing problem among otherwise healthy people. And although the infection can usually be controlled with antibiotics, virulent strains of C. difficile are now appearing that resist treatment with common medications. What can be done about this growing problem. Researchers will describe novel treatments for this disease including an experimental drug that inhibits sporulation and toxin production by the bacteria. Another is a strategy using the same compounds antibiotic resistant bacteria use to protect the good bacteria in the colon preventing C. difficile from gaining a foothold during antibiotic therapy.
		Are Daycare Centers Safer in the Era of New Vaccines? Robert Cohen, ACTIV, Saint Maur, France. Ron Dagan, Ben-Gurion University, Beer-Sheva, Israel. Janet England, Children's Hospital and Regional Medical Center, Seattle, Washington, USA. Larry Pickering, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Jane Seward, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.	Daycare centers have long had a reputation of giant petri dishes, where young children mix and mingle, trading illnesses and bringing them home. But in the last decade a number of new vaccines have been approved to prevent many of these diseases in young children, including chicken pox, Streptococcus pneumoniae (a common cause of ear infections), rotavirus (a common cause of diarrhea and gastrointestinal infections) and hepatitus A. Have these vaccines made daycare safer not only for the children, but for their families as well? Researchers will present data on the impact these and other vaccines have had on the incidence of daycare associated disease.
		Social & Medical Issues in HIV
		HIV Infection in Women